Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 17, 2020 08:30 ET | Source: aTyr Pharma, Inc.

Leading Cancer Researcher Dr. Arthur M. Mercurio Joins aTyr as Scientific Advisor

SAN DIEGO, March 17, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
March 10, 2020 08:30 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Exercise and Closing of Over-Allotment Option in Public Offering

SAN DIEGO, March 10, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
March 03, 2020 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting

SAN DIEGO, March 03, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
February 27, 2020 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Publication in the Journal Cellular and Molecular Immunology

Paper highlights the essential role that histidyl tRNA synthetase (HARS) plays in immune responses in a broad range of inflammatory disease states Lead therapeutic candidate, ATYR1923, being...
February 06, 2020 09:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Pricing of $18 million Underwritten Public Offering

SAN DIEGO, Feb. 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
January 06, 2020 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of ATYR1923 in Japan

aTyr eligible to receive up to $175 million in total payments, including $8 million upfront, plus tiered sales royalties Kyorin to fund all ATYR1923 development and commercialization activities in...
December 12, 2019 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Positive Interim Safety Results from Ongoing Phase 1b/2a Clinical Trial of ATYR1923

ATYR1923 safe and well tolerated in initial 15 randomized patients with pulmonary sarcoidosis No drug-related serious adverse events observed SAN DIEGO, Dec. 12, 2019 (GLOBE NEWSWIRE) -- aTyr...
November 14, 2019 16:01 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Third Quarter 2019 Results and Provides Corporate Update

Interim safety results from Phase 1b/2a proof-of-concept trial of ATYR1923 in pulmonary sarcoidosis patients due in December 2019 Company to host conference call and webcast today, November 14, at...
November 13, 2019 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at the Stifel Healthcare Conference 2019

SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
November 07, 2019 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Announce Third Quarter Results on November 14th

SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...